Specifically, thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, are specific PPARγ activators and are used as insulin sensitizers in order to improve insulin resistance in T2DM patients. This evidence concerns the gene PPARG and type 2 diabetes mellitus.